Clinical trial · Observational
German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) To perform morphologic and genetic analyses To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) To assess quality of life
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BCR-ABL1-Negative Myeloid Neoplasms | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Registry study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Treatment decision
- timeFrame
- 25 years
- description
- Treatment decision (watch and wait, standard, investigational)
- measure
- Response
- timeFrame
- 25 years
- description
- Response of treatment
- measure
- Overall survival
- timeFrame
- 25 years
- description
- Survival over the whole study duration
- measure
- Progression-free-survival
- timeFrame
- 25 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Both female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry: * Patients with BCR-ABL 1-myeloid neoplasia according to WHO classification or IWG MRI criteria * Age ≥ 18 years. There is no upper age limit. * Signed written informed consent. Exclusion Criteria: * Severe neurological or psychiatric disorder interfering with ability to give an informed consent * No consent for registration, storage and handling of the personal data
References
Publications (0)
Data not yet available